See the DrugPatentWatch profile for Yupelri
The cost of Yupelri (revefenacin) for patients with Blue Cross Blue Shield (BCBS) insurance can vary significantly depending on individual plan details, including deductibles, copays, and coinsurance. There is no single set cost for Yupelri with BCBS coverage.
What factors influence Yupelri's price for BCBS members?
The final out-of-pocket cost for Yupelri for individuals with BCBS insurance is determined by several factors. These include the specific BCBS plan purchased, whether the patient has met their annual deductible, the plan's copayment or coinsurance for specialty medications, and whether Yupelri is covered by the plan at all [1].
How can I estimate Yupelri's cost with my insurance?
To get an accurate estimate of Yupelri's cost with BCBS coverage, individuals should contact their specific BCBS provider. This can typically be done by calling the member services number on the back of their insurance card or by logging into their online BCBS account. They can also ask their prescribing physician's office, as they often have experience navigating the costs and coverage for specific medications.
Are there patient assistance programs for Yupelri?
Yes, there are patient assistance programs available that may help reduce the out-of-pocket cost of Yupelri. The manufacturer of Yupelri, Theravance Biopharma, offers programs that could provide financial assistance to eligible commercially insured patients. Details on these programs, including eligibility requirements and how to apply, can usually be found on the Yupelri website or by contacting the manufacturer directly [1].
When does Yupelri's patent exclusivity expire?
Information on Yupelri's patent exclusivity can be found through resources that track drug patents. DrugPatentWatch.com provides data on patent expiry dates for various medications. Specific patent expiry information for Yupelri would be available through such specialized databases [2].
How does Yupelri work for COPD?
Yupelri is a long-acting muscarinic antagonist (LAMA) used to treat airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). It works by relaxing the muscles around the airways in the lungs, which helps to open them up and make breathing easier [1].